{
    "clinical_study": {
        "@rank": "36738", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Dose 1"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Dose 2"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo\n      controlled, pediatric study conducted in three phases."
        }, 
        "brief_title": "Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)", 
        "completion_date": {
            "#text": "June 2008", 
            "@type": "Actual"
        }, 
        "condition": "Systemic Juvenile Idiopathic Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Juvenile Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria include, but are not limited to, the following:\n\n          -  Patients aged 4 to less than 21 years who meet the criteria for active SJIA\n\n          -  Must have been on a stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) for\n             at least 4 weeks prior to the screening visit\n\n        Exclusion Criteria include, but are not limited to, the following:\n\n          -  Use of certain medications prior to the baseline visit\n\n          -  History of recurrent infections"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803321", 
            "org_study_id": "IL1T-AI-0504"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "intervention_name": "rilonacept (IL-1 Trap)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "SJIA", 
        "lastchanged_date": "February 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "Delaware"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Long Island", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)", 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Frequency of treatment emergent adverse events (TEAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to Week 123"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803321"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2005", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}